GREAT BASIN SCIENT (GBSN)

0.03
0.00 9.86
OTC
Prev Close 0.04
Open 0.04
Day Low/High 0.03 / 0.04
52 Wk Low/High 0.01 / 0.06
Volume 26.62K
Exchange OTC
Shares Outstanding 74.00M
Market Cap 329.70K
Div & Yield N.A. (N.A)

Latest News

Data To Be Presented At ASM Microbe 2017 Demonstrates The Efficacy Of Great Basin's Stool Bacterial Pathogens Panel

Four posters describing the Company's platform to be presented, including a third-party clinical study poster of the Stool Bacterial Pathogens Panel

Great Basin Scientific Issued Second U.S. Patent For PCR Amplification Suppressor

New patent extends protection to all the Company's assays; Company to explore licensing opportunities with non-competing entities

Great Basin Scientific Announces Commercial Launch Of Bordetella Direct Test

Assay for Bordetella pertussis, or whooping cough, shipping to U.S. customers; Company also announces CE Marking

Great Basin Scientific Obtains Release Of $1.36 Million Of Restricted Cash From Series B Convertible Notes

Eliminates variable-price mandatory conversion feature

Great Basin Scientific Receives CE Marking For Stool Bacterial Pathogens Panel

Company also has more than 40 sites in the U.S. currently evaluating or committed to evaluate under Investigational Use Only (IUO) labeling

Study Published In PLOS ONE Demonstrates Effectiveness Of Great Basin Scientific's Patented Amplification Suppressor Technology

Technology shown to distinguish disease-causing potentially life-threatening Staphylococcus strains from Staphylococcus present due to environmental contamination, supporting more accurate diagnosis, better patient care and healthcare cost savings

Great Basin Scientific Receives FDA 510(k) Clearance For Bordetella Direct Test

Sample-to-result test for Bordetella pertussis, or whooping cough, receives clearance in fewer than 60 days from submission

Great Basin Scientific's Suzette Chance Named A 2017 Woman Worth Watching In STEM By Profiles In Diversity Journal

Senior Director of Regulatory and Clinical Affairs recognized for scientific leadership and career accomplishments

Great Basin Scientific's Staph ID/R Blood Culture Panel Clinical Evaluation And Rapid Identification Analysis Published In Journal Of Clinical Microbiology

Multicenter evaluation demonstrates Staph ID/R Blood Culture Panel's efficacy in rapid identification of Staphylococci and detection of mecA gene

Great Basin Scientific's Shiga Toxin Direct Test Clinical Evaluation And Cost Analysis Published In Journal Of Clinical Microbiology

Study validates that Great Basin's assay provides cost effective, rapid and definitive detection of Shiga Toxin-producing E.coli

Great Basin Scientific Completes Clinical Trial, Submits FDA 510(k) Application For Bordetella Direct Test

Upon FDA clearance, Company's sample-to-result test will offer cost effective and easy-to-use testing for Bordetella pertussis or whooping cough

Great Basin Announces Request To Withdraw S-1 Registration Statement And Amendment To $75 Million 2016 Convertible Note

Great Basin Announces Request To Withdraw S-1 Registration Statement And Amendment To $75 Million 2016 Convertible Note

Company determines additional funding likely unnecessary to meet 2017 needs

Great Basin Scientific Stock Symbol Temporarily Changed To GBSND

Great Basin Scientific Stock Symbol Temporarily Changed To GBSND

Company Stock Trades Under GBSND for 20 Days; Reverts to GBSN After

Great Basin Announces Effectiveness Of Reverse Stock Split Of Common Stock And Authorized Share Increase

Great Basin Announces Effectiveness Of Reverse Stock Split Of Common Stock And Authorized Share Increase

Company has 663,334 shares of common stock outstanding post-split; 1,500,000,000 authorized shares

Great Basin Scientific Shareholders Approve Reverse Stock Split And Authorized Share Increase During Special Meeting

Great Basin Scientific Shareholders Approve Reverse Stock Split And Authorized Share Increase During Special Meeting

Board of Directors Approve 1-for-300 Reverse Stock Split and Sets Effective Date for Reverse Stock Split and Authorized Share Increase

Great Basin Scientific Submits 510(k) Application To The FDA For Stool Bacterial Pathogens Panel

Great Basin Scientific Submits 510(k) Application To The FDA For Stool Bacterial Pathogens Panel

Upon anticipated FDA clearance, Company's syndromic panel will provide cost effective identification for common gastrointestinal pathogens